The goal of the Mayo SPORE In Brain Cancer Developmental Research Program (DRP) is to support innovative and scientifically sound projects that investigate questions pertaining to some aspect of translational research in malignant gliomas and other primary brain tumors. The DRP will provide two one year awards of $50,000 each. Dr. Robert B. Jenkins, overall Co-PI of the SPORE, will direct the program. The premise of this program is that support of developmental research projects will result in the generation of new hypotheses that will be tested within SPORE-sponsored projects or through peer-reviewed external grant support. The long-term goal of the program Is to translate the findings generated by developmental grants into effective interventions in patients with, and persons at risk for, primary brain tumors. An equally important goal is the attraction of new Investigators and their expertise to the challenges of brain cancer research. The DRP objectives are to: (1) stimulate Innovative and translationally-relevant laboratory, population science and clinical studies in primary brain tumors;(2) foster extensive collaboration between basic science, population science and clinical disciplines to advance brain tumor translational research, and (3) encourage investigators in related fields to apply their expertise to translational research in brain tumors. The Program will be administered through the Administrative Core of the SPORE. One-page outlines of two potential research projects are included to demonstrate the depth and breadth of ongoing research that can be eligible for funding through the SPORE Developmental Research Program. These two potential projects represent under-developed areas within glioma research.

Public Health Relevance

The Mayo SPORE in Brain Cancer Developmental Research Program was established to fund early phase research that take maximum advantage of SPORE resources to generate feasibility data for projects that have the highest translational potential. In so doing the DRP will develop scientists who will advance and significantly impact the nation's brain tumor agenda.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Geekiyanage, Hirosha; Galanis, Evanthia (2016) MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol 10:1387-1403
Rajani, Karishma; Parrish, Christopher; Kottke, Timothy et al. (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther 24:166-74
Ma, Yufang; Tang, Nan; Thompson, Reid C et al. (2016) InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 22:1767-76
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol :
Vaubel, Rachael A; Chen, Selby G; Raleigh, David R et al. (2016) Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. J Neuropathol Exp Neurol 75:44-52
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2016) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol :
Zhang, Haoxing; Liu, Hailong; Chen, Yali et al. (2016) A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun 7:10201
Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43
Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98
Cockle, Julia V; Rajani, Karishma; Zaidi, Shane et al. (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18:518-27

Showing the most recent 10 out of 220 publications